1 Erratum to: Clin Drug Investig DOI 10.1007/s40261-017-0532-1

The following correction should be noted:

Key Points, last sentence, which previously read:

There are reliable real-world data showing poroctant alfa is effective and well tolerated in children/infants with ARDS.

Should read:

There are reliable real-world data showing poractant alfa (Curosurf®) is effective and well tolerated in children/infants with ARDS.